The sector has been red hot. It is due for a pause and a test of the breakout. Perhaps this is where we get that healthy pause and refresh or perhaps we have a little more juice left in this move. Yesterday was interesting with a pretty strong move in the big pharma names. I […]
July 15th Biotech Update
A little bit of strength to start the week. I still think we need to pause this run higher and back test support. We clearly seem to be breaking out of a range and to confirm that break I would like to see us test the upper end of that range as support. I think […]
Cardiol Therapeutics: MAvERIC-Pilot Results Achieve CardiolRx™ Proof-of-Concept as an Active Drug for Recurrent Pericarditis
Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is a life sciences company developing pharmaceutically manufactured cannabidiol formulations (CardiolRx™ and CRD-38) as innovative therapies for heart diseases, including recurrent pericarditis (RP), acute myocarditis, and heart failure. We previously covered the company and its pipeline extensively (LINK) prior to and in preparation for the MAvERIC-Pilot trial (NCT05494788) readout […]
July 12th Biotech Update
It has been a really good week. If you look at the chart, one could make a compelling case that we are breaking out of that range. I would not have predicted this was the week in which that would happen but it looks good. If I were writing the ideal script we would extend […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
